In a report released yesterday, Michael Schmidt from Guggenheim maintained a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report), with a price target of $6.00. The company’s shares opened today at $1.24.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Schmidt covers the Healthcare sector, focusing on stocks such as Compass Therapeutics, Exelixis, and BeiGene. According to TipRanks, Schmidt has an average return of 13.4% and a 48.30% success rate on recommended stocks.
In addition to Guggenheim, Zentalis Pharmaceuticals also received a Buy from Oppenheimer’s Matthew Biegler in a report issued today. However, on the same day, Wells Fargo maintained a Hold rating on Zentalis Pharmaceuticals (NASDAQ: ZNTL).
Based on Zentalis Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $26.87 million and a GAAP net loss of $47.47 million. In comparison, last year the company earned a revenue of $2.1 million and had a GAAP net loss of $60.92 million
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ZNTL in relation to earlier this year. Last month, Scott Dunseth Myers, a Director at ZNTL bought 21,000.00 shares for a total of $29,190.00.
Read More on ZNTL:
- Zentalis price target lowered to $9 from $10 at Oppenheimer
- Zentalis Pharmaceuticals: Hold Rating Maintained Amid Lack of Short-Term Catalysts and Stock Decline
- Zentalis Pharmaceuticals: Promising Clinical Trials and Potential for Accelerated Approval Justify Buy Rating
- Zentalis reports Q1 EPS (67c), consensus (61c)
- Zentalis announces first patient dosed in DENALI Part 2 trial of azenosertib